20-Valent Pneumococcal Vaccine Approved for Clinical Trials
January 20, 2026
Source: drugdu
32
On January 19, AIM Vaccine (06660.HK) issued an announcement stating that its self-developed 20-valent pneumococcal polysaccharide conjugate vaccine (PCV20) has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA), officially granting approval for clinical trials.
The vaccine is an optimized upgrade of the 13-valent pneumococcal conjugate vaccine (PCV13), adding 7 new serotypes for a total of 20 major prevalent serotypes. It is designed to prevent invasive diseases caused by these serotypes, such as pneumonia, meningitis, and bacteremia.
https://finance.eastmoney.com/a/202601193623487020.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- ADC205 Tablets Received Approval for Drug Clinical Trial January 20, 2026
- Sifang Optoelectronics makes strategic investment in Changhe Biotechnology January 20, 2026
- Mingde Bio plans to acquire a 51% stake in Hunan Lanyi through capital increase and acquisition January 20, 2026
- accelerating the transition of CLL treatment into a “chemotherapy-free era”. January 20, 2026
- Clinical trials successful, development terminated. January 20, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
